Daiwa Securities Group
PRVB

Daiwa Securities Group’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Daiwa Securities Group’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-351
Closed -$8K – 1378
2023
Q1 		$8K Hold
351
– – ﹤0.01% 1129
2022
Q4 		$4K Buy
351
+245
+231% +$1.98K ﹤0.01% 1179
2022
Q3 		$0 Hold
106
– – ﹤0.01% 1431
2022
Q2 		$0 Hold
106
– – ﹤0.01% 1464
2022
Q1 		$1K Hold
106
– – ﹤0.01% 1365
2021
Q4 		$1K Hold
106
– – ﹤0.01% 1377
2021
Q3 		$1K Hold
106
– – ﹤0.01% 1300
2021
Q2 		$1K Hold
106
– – ﹤0.01% 1245
2021
Q1 		$1K Hold
106
– – ﹤0.01% 1256
2020
Q4 		$2K Buy
+106
New +$1.59K ﹤0.01% 1149

Other funds holding PRVB

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Daiwa Securities Group's PRVB Position: Q2 2023 in Review

Daiwa Securities Group sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 351 shares — an estimated $8K sold.

Daiwa Securities Group first reported a position in PRVB in Q4 2020 and held it in 10 quarters. The position peaked at $8K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • Daiwa Securities Group reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Daiwa Securities Group sold 351 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $8K.
  • Daiwa Securities Group first reported a position in Provention Bio, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
  • Daiwa Securities Group's Provention Bio, Inc. Common Stock position peaked at $8K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Daiwa Securities Group's 13F filing for Q2 2023, filed 31 Jul 2023.